| |
|
Product Name:
|
AKU-2017-385
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Classification: Mitosporic Saccharomycetaceae, Candida
Species: Candida auris (also referred to as Candidozyma auris)1
Strain: AKU-2017-385
|
|
Additional Information:
|
C. auris is an emerging multidrug-resistant pathogenic yeast, which causes invasive infections and outbreaks in nosocomial settings, resulting in high mortality. Since it was first described in 2009, C. auris has been isolated in over 30 countries on 6 continents, with the earliest known isolate from 1996 discovered during a retrospective review of unidentified yeasts.3 C. auris is unique among disease-causing yeasts in that it behaves more like transmissible multidrug-resistant bacteria in healthcare settings, capable of transmission between patients through shedding and requiring specific control measures.3,4 Infections primarily affect patients with underlying medical conditions or who have had recent surgery. C. auris is capable of colonizing patients in both sterile and non-sterile sites such as skin, and is known to colonize and persist in the environment, including on healthcare surfaces and equipment, such as catheters, attributed to biofilm formation.5,6 Misidentification by commercial biochemical tests, often as closely related C. haemulonii, delays treatment and implementation of control measures.5,6
C. auris has a strong phylogeographic structure comprising four distinct clades, South Asia, East Asia, South Africa and South America, separated by tens of thousands of SNPs, with smaller clusters identified in some clades.4 This high level of relatedness and low genetic diversity within clades suggests clades emerged independently and near-simultaneously in four distinct locations rather than a single spread.3,4,5
Reclassification of C. auris to Candidozyma auris has been proposed.1
|
|
Material Provided:
|
Each vial contains approximately 0.5 mL of yeast culture in 20% glycerol.
|
|
Packing/Storage:
|
NR-52713 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Media:
Sabouraud Dextrose broth or Yeast Mold agar or equivalent
Sabouraud Dextrose broth or Yeast Mold agar or equivalent
Incubation:
Temperature: 25°C to 30°C
Atmosphere: Aerobic
Propagation:
1. Keep vial frozen until ready for use; thaw rapidly in a water bath at 25°C to 30°C. Typically, this takes less than 5 minutes.
2. Immediately after thawing, inoculate an agar plate with approximately 50 µL of thawed culture and/or transfer the entire thawed aliquot into a single tube of broth.
3. Incubate the plate and/or tube at 25°C to 30°C for 2 to 4 days.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Liu, F., et al. “Phylogenomic Analysis of the Candida auris – Candida haemuli Clade and Related Taxa in the Metschnikowiaceae, and Proposal of Thirteen New Genera, Fifty-Five New Combinations and Nine New Species.” Persoonia 52 (2024): 22-43. PubMed: 39161632.
2. Farooqi, J., Personal Communication.
3. Forsberg, K., et al. “Candida auris: The Recent Emergence of a Multidrug-Resistant Fungal Pathogen.” Med. Mycol. 57 (2019): 1-12. PubMed: 30085270.
4. Lockhart, S. R., et al. “Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.” Clin. Infect. Dis. 64 (2017): 134-140. PubMed: 27988485.
5. Tsay, S., et al. “Approach to the Investigation and Management of Patients with Candida auris, an Emerging Multidrug-Resistant Yeast.” Clin. Infect. Dis. 66 (2018): 306-311. PubMed: 29020224.
6. Spivak, E. S. and K. E. Hanson. “Candida auris: An Emerging Fungal Pathogen.” J. Clin. Microbiol. 56 (2018): e01588-17. PubMed: 29167291.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Candida auris, Strain AKU-2017-385, NR-52713.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|